mash wegovy - Search News

Order byBest matchMost fresh

Novo Nordisk, MASH

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

BioPharma Dive · 1d

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

Investor's Business Daily on MSN · 1d

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

· 23h

Novo Nordisk (NVO) Receives FDA Approval for Wegovy

On August 15, Novo Nordisk (NYSE:NVO) announced that the FDA had approved the use of its new drug Wegovy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis.

· 1d

Stocks to Watch Monday: Novo Nordisk, TeraWulf, UnitedHealth, Soho House

· 1d

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

· 12h

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

The approval is based on results from the first phase of the ESSENCE trial, which revealed Wegovy’s superior efficacy over placebo in improving liver fibrosis.

· 1d

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

· 1d

NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?

Medscape1d

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis but without cirrhosis.

Endocrinology Advisor1d

Wegovy Approved for Noncirrhotic MASH With Moderate, Advanced Liver Fibrosis

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

BioSpace1d

Novo Wins MASH Approval for Wegovy

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according to analysts at BMO Capital Markets.

GlobalData on MSN1d

Wegovy becomes first GLP-1RA to gain FDA MASH approval

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).